Showing 2561-2570 of 6036 results for "".
- Optos Celebrates Milestones: 25,000 Devices Installed Globally and Extensive Clinical Publications Achievedhttps://modernod.com/news/optos-celebrates-milestones-25000-devices-installed-globally-and-extensive-clinical-publications-achieved/2482131/Optos announced a dual milestone achievement of over 25,000 devices installed worldwide, and the collection of 2,500 clinical and peer-reviewed studies spanning 235 disease states, acccording to a company news release. "This remarkable double milestone reflects the unwavering
- Ocular Therapeutix Announces Board of Directors and Leadership Updateshttps://modernod.com/news/ocular-therapeutix-announces-board-of-directors-and-leadership-updates/2482128/Ocular Therapeutix announced Board of Directors and leadership updates with the addition of Pravin U. Dugel, MD as Executive Chairman; and the additions of Jeffrey S. Heier, MD, Peter K. Kaiser, MD, and Sanjay Nayak, MBBS, PhD, to the Ocular management
- FDA Gives Green Light to Okyo Pharma for Clinical Trial Design for OK-101 in Neuropathic Corneal Painhttps://modernod.com/news/fda-gives-green-light-to-okyo-pharma-for-clinical-trial-design-for-ok-101-in-neuropathic-corneal-pain/2482109/Okyo Pharma announced that the FDA has cleared OK-101 as its first investigational new drug (IND) application for the treatment of Neuropathic Corneal Pain (NCP). The initial IND submission to FDA proposed an open-label design for the clinical trial. Based on positiv
- Nicox and Kowa Enter into Agreement for NCX 470 Development and Commercialization in Japanhttps://modernod.com/news/nicox-and-kowa-enter-into-agreement-for-ncx-470-development-and-commercialization-in-japan/2482106/Nicox SA announced the signature of an agreement granting Kowa exclusive Japanese rights to develop and commercialize NCX 470, Nicox’s nitric oxide (NO)-donating bimatoprost eye drop for the lowering of IOP in patients with glaucoma or ocular hypertension. Under the
- Opthea Names New Clinical and Regulatory Leadership Membershttps://modernod.com/news/opthea-names-new-clinical-and-regulatory-leadership-members/2482091/Opthea announced the appointment of Julie Clark, MD, MS, as Senior Vice President (SVP), Clinical Development; and Fang Li, PhD, RAC, as SVP, Regulatory Affairs, effective February 1, 2024. Dr. Clark and Dr. Li will report to Opthea Chief Executive Officer Frederic Guerard, PharmD,
- Théa Acquires Rights to KIO-301 for the Treatment of Inherited Retinal Diseases in $301 Million Dealhttps://modernod.com/news/thea-acquires-rights-to-kio-301-for-the-treatment-of-inherited-retinal-diseases-in-301-million-deal/2482089/Kiora Pharmaceuticals announced that it has entered a strategic development and commercialization agreement with Théa Open Innovation (TOI), a sister company of Laboratoires Théa under with Kiora granted Théa exclusive worldwide development and commercialization rig
- Coherus Divest Ophthalmology Franchise to Sandoz in $170 Million Dealhttps://modernod.com/news/coherus-divest-ophthalmology-franchise-to-sandoz-in-170-million-deal/2482075/In a move to pay down debt and focus on its oncology business, Coherus BioSciences has entered into an agreement to divest its Cimerli (ranibizumab-eqrn) ophthalmology franchise to Sandoz for $170 million in cash, plus Cimerli inventory costs. This divestiture includes Co
- Regenxbio Announces Interim Data from Phase 2 AAVIATE Trial of ABBV-RGX-314 for Wet AMD Using Suprachoroidal Deliveryhttps://modernod.com/news/regenxbio-announces-interim-data-from-phase-2-aaviate-trial-of-abbv-rgx-314-for-the-treatment-of-wet-amd-using-suprachoroidal-delivery/2482066/Regenxbio announced positive interim data from the phase 2 AAVIATE trial of ABBV-RGX-314 for the treatment of wet age-related macular degeneration (AMD) using suprachoroidal delivery. Investigational ABBV-RGX-314 is designed to be a one-time, in office treatment that has the potent
- Decision on the Adoption of a Sale Plan for Pixium Vision Postponedhttps://modernod.com/news/decision-on-the-adoption-of-a-sale-plan-for-pixium-vision-postponed/2482065/Pixium Vision announced that the decision of the Paris Commercial Court on the takeover offer filed on November 20, 2023 and the opening of judicial liquidation proceedings has been postponed to a later date, which will be communicated by the company as soon as it becomes aware of it.</
- OrCam Unveils Enhancements for MyEye and Read3 Devices at CEShttps://modernod.com/news/orcam-unveils-enhancements-for-myeye-and-read3-devices-at-ces/2482050/OrCam Technologies, which is focused on personal artificial intelligence (AI) assistive technology platforms, introduced new enhancements for its MyEye and Read3 devices at CES 2024, the Consumer Electronics Show held by the Consumer Technology Association on January 9-12 in Las Vegas, Nevada.